Enanta Pharmaceuticals Inc (ENTA)

31.86
0.35 1.10
NASDAQ : Health Care
Prev Close 32.21
Open 32.09
Day Low/High 31.63 / 32.62
52 Wk Low/High 16.75 / 51.89
Volume 18.72K
Avg Volume 232.40K
Exchange NASDAQ
Shares Outstanding 19.04M
Market Cap 627.04M
EPS 1.10
P/E Ratio 21.81
Div & Yield N.A. (N.A)

Latest News

Enanta Pharmaceuticals Announces AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

Enanta Pharmaceuticals Announces AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced 98 percent...

Enanta Announces Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

Enanta Announces Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie has...

Enanta Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting® 2016

Enanta Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting® 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data...

Enanta Pharmaceuticals To Host Conference Call On November 21 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals To Host Conference Call On November 21 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference

Enanta Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Stock Sees Short Interest Move 15.2% Lower

Enanta Pharmaceuticals Stock Sees Short Interest Move 15.2% Lower

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 369,069 share decrease in total short interest for Enanta Pharmaceuticals, Inc. , to 2,066,341, a decrease of 15.15% since 09/15/2016.

Enanta Pharmaceuticals Announces New Data Presentations At The Liver Meeting® 2016

Enanta Pharmaceuticals Announces New Data Presentations At The Liver Meeting® 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that six poster...

Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)

Enanta Pharmaceuticals Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference

Enanta Pharmaceuticals Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that a poster...

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-alcoholic Steatohepatitis (NASH)

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-alcoholic Steatohepatitis (NASH)

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has...

Commit To Buy Enanta Pharmaceuticals At $20, Earn 11.5% Annualized Using Options

Commit To Buy Enanta Pharmaceuticals At $20, Earn 11.5% Annualized Using Options

Investors eyeing a purchase of Enanta Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $26.27/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Pharmaceuticals Announces Data On Eight-Week Treatment Of AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

Enanta Pharmaceuticals Announces Data On Eight-Week Treatment Of AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data showing...

AbbVie Presents Data On Eight-Week Treatment Of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

AbbVie Presents Data On Eight-Week Treatment Of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C

- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1

Enanta Pharmaceuticals Reaches Analyst Target Price

Enanta Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Enanta Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $24.00, changing hands for $24.24/share.

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Announces The U.S. Food And Drug Administration Has Approved AbbVie's New, Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus

Enanta Announces The U.S. Food And Drug Administration Has Approved AbbVie's New, Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis

Enanta Pharmaceuticals To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Commit To Buy Enanta Pharmaceuticals At $19, Earn 12.7% Annualized Using Options

Commit To Buy Enanta Pharmaceuticals At $19, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of Enanta Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $23.72/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus

Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated...

Enanta Pharmaceuticals is Now Oversold (ENTA)

Enanta Pharmaceuticals is Now Oversold (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Trade-Ideas LLC identified Enanta Pharmaceuticals (ENTA) as a strong on high relative volume candidate

ENTA: Insiders vs. Shorts

ENTA: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Enanta Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 11.09 "days to cover" versus the median component at 6.16.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.